Labcorp stock falls as CMS proposes 15 percent reimbursement cuts

Published on 09/22/2026 at 20:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock fell 5.9 percent in premarket trading on September 22, 2026, after CMS proposed laboratory reimbursement cuts of up to 15 percent. Truist raised its target to USD 365.

Aquarellbild eines gläsernen Bürogebäudes vor Skyline in Pastelltönen — Aquarellmalerei einer Stadtlandschaft mit gläsernem Firmensitz symbolisiert Labcorp, ISIN US50540R4092, im Gesundheitssektor, Illustration mit AI erstellt.

Labcorp Holdings Inc. (ISIN US50540R4092) fell 5.9 percent to USD 254.42 in premarket trading on September 22, 2026, after proposed US reimbursement reductions of up to 15 percent put laboratory stocks under pressure. The policy proposal creates a direct earnings risk for the company, although Truist Securities raised its Labcorp price target from USD 350 to USD 365 on the same date.

CMS proposal hits laboratory shares

According to TradingView on September 22, 2026, diagnostic-testing shares declined after the Centers for Medicare and Medicaid Services proposed cuts to Medicare payment rates for laboratory services. The preliminary 2027 Clinical Laboratory Fee Schedule includes annual reimbursement reductions of up to 15 percent, according to Investing.com.

The market reaction was broad across the laboratory sector. TradingView reported Labcorp down 5.9 percent at USD 254.42 in premarket trading, while Quest Diagnostics declined 6.9 percent to USD 227.90 on September 22, 2026. The proposed 15 percent ceiling is therefore the key quantified risk for revenue and margin assumptions tied to Medicare testing.

Analyst target moves higher

The policy risk has not led every analyst to reduce expectations. According to Aktiencheck on September 22, 2026, Truist Securities lifted its Labcorp price target from USD 350 to USD 365 and kept a Buy rating. The USD 15 increase contrasts with the proposed reimbursement reduction and shows how analysts are weighing regulatory pressure against the companys longer-term fundamentals.

The same report stated that Labcorp raised its adjusted full-year earnings-per-share range by USD 0.30 at the midpoint to USD 18.10 to USD 18.55. That guidance comparison is material: the midpoint increased from USD 18.00 to USD 18.30, while the reimbursement proposal introduces a separate policy variable for 2027 rather than changing the 2026 range in the cited report.

Stock trades below yearly high

Labcorp closed at USD 320.71 on the NYSE on September 21, 2026, down 0.63 percent from the prior session, according to the quoted market data in the September 22 market update. The stock then traded within a 52-week range of USD 244.52 to USD 341.80, leaving the prior close USD 21.09 below the high and USD 76.19 above the low.

Another September 22 market snapshot showed Labcorp at USD 321.27, with a market capitalization of USD 26.05 billion and a 200-day simple moving average of USD 283.41. These figures place the shares above the long-term average cited in that snapshot, but the proposed 2027 payment cuts remain the central counter-factor for valuation.

Labcorp stock closes after policy shock

Labcorp stock closed at USD 320.71 on the NYSE on September 21, 2026, after the previous session produced a 0.63 percent decline. The next market reaction on September 22 centered on the proposed reimbursement cuts of up to 15 percent, while Truist Securities cited a USD 365 target and Labcorp guidance of USD 18.10 to USD 18.55 in adjusted earnings per share.